Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines

Peter L. Greenberg; Richard M. Stone; Yasmin Abaza; Aref Al-Kali; Sarah Anand; Brian Ball; John M. Bennett; Uma Borate; Andrew M. Brunner; Wanxing Chai-Ho; Peter Curtin; Amy E. DeZern; Karin Gaensler; Zhubin Gahvari; Guillermo Garcia-Manero; Elizabeth A. Griffiths; Tamanna Haque; Meagan Jacoby; Brian A. Jonas; Sioban Keel; Rashmi Khanal; Ashwin Kishtagari; Yazan Madanat; Lori J. Maness; Shannon R. McCurdy; Christine McMahon; Olatoyosi Odenike; Afaf Osman; Vishnu V. Reddy; David A. Sallman; Hamid Sayar; Rory Shallis; Abhay Singh; Tiffany Tanaka; Swapna Thota; Emily Kovach; Jamie Nguyen; Cindy Hochstetler

doi:10.6004/jnccn.2025.0013

Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines

Peter L. Greenberg
, Richard M. Stone
, Yasmin Abaza
, Aref Al-Kali
, Sarah Anand
, Brian Ball
, John M. Bennett
, Uma Borate
, Andrew M. Brunner
, Wanxing Chai-Ho
, Peter Curtin
, Amy E. DeZern
, Karin Gaensler
, Zhubin Gahvari
, Guillermo Garcia-Manero
, Elizabeth A. Griffiths
, Tamanna Haque
, Meagan Jacoby
, Brian A. Jonas
, Sioban Keel

Rashmi Khanal, Ashwin Kishtagari, Yazan Madanat, Lori J. Maness, Shannon R. McCurdy, Christine McMahon, Olatoyosi Odenike, Afaf Osman, Vishnu V. Reddy, David A. Sallman, Hamid Sayar, Rory Shallis, Abhay Singh, Tiffany Tanaka, Swapna Thota, Emily Kovach, Jamie Nguyen, Cindy Hochstetler

Office of Research Compliance

Stanford University
Dana-Farber/Brigham and Women's Cancer Center
Northwestern University
Mayo Clinic Rochester, MN
University of Michigan, Ann Arbor
City of Hope National Med Center
University of Rochester
Ohio State University
Mass General Cancer Center
University of California at Los Angeles
Johns Hopkins University
University of California at San Francisco
University of Wisconsin
University of Texas MD Anderson Cancer Center
Memorial Sloan-Kettering Cancer Center
Washington University St. Louis
University of California at Davis
Fred Hutchinson Cancer Research Center
Fox Chase Cancer Center
Vanderbilt University
UT Southwestern Simmons Comprehensive Cancer Center
University of Nebraska Medical Center
University of Pennsylvania
University of Colorado Anschutz Medical Campus
The University of Chicago
University of Utah
University of Alabama at Birmingham
Moffitt Cancer Center
Indiana University Bloomington
Yale University
Case Western Reserve University
University of California at San Diego
University of Tennessee Health Science Center
National Comprehensive Cancer Network

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

Original language	English
Pages (from-to)	66-75
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	23
Issue number	3
DOIs	https://doi.org/10.6004/jnccn.2025.0013
State	Published - Mar 2025

Access to Document

10.6004/jnccn.2025.0013

Cite this

Greenberg, P. L., Stone, R. M., Abaza, Y., Al-Kali, A., Anand, S., Ball, B., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., DeZern, A. E., Gaensler, K., Gahvari, Z., Garcia-Manero, G., Griffiths, E. A., Haque, T., Jacoby, M., Jonas, B. A., ... Hochstetler, C. (2025). Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 23(3), 66-75. https://doi.org/10.6004/jnccn.2025.0013

@article{46be2e37833b445a86247fc201e415df,

title = "Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.",

author = "Greenberg, \{Peter L.\} and Stone, \{Richard M.\} and Yasmin Abaza and Aref Al-Kali and Sarah Anand and Brian Ball and Bennett, \{John M.\} and Uma Borate and Brunner, \{Andrew M.\} and Wanxing Chai-Ho and Peter Curtin and DeZern, \{Amy E.\} and Karin Gaensler and Zhubin Gahvari and Guillermo Garcia-Manero and Griffiths, \{Elizabeth A.\} and Tamanna Haque and Meagan Jacoby and Jonas, \{Brian A.\} and Sioban Keel and Rashmi Khanal and Ashwin Kishtagari and Yazan Madanat and Maness, \{Lori J.\} and McCurdy, \{Shannon R.\} and Christine McMahon and Olatoyosi Odenike and Afaf Osman and Reddy, \{Vishnu V.\} and Sallman, \{David A.\} and Hamid Sayar and Rory Shallis and Abhay Singh and Tiffany Tanaka and Swapna Thota and Emily Kovach and Jamie Nguyen and Cindy Hochstetler",

year = "2025",

month = mar,

doi = "10.6004/jnccn.2025.0013",

language = "English",

volume = "23",

pages = "66--75",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "3",

}

Greenberg, PL, Stone, RM, Abaza, Y, Al-Kali, A, Anand, S, Ball, B, Bennett, JM, Borate, U, Brunner, AM, Chai-Ho, W, Curtin, P, DeZern, AE, Gaensler, K, Gahvari, Z, Garcia-Manero, G, Griffiths, EA, Haque, T, Jacoby, M, Jonas, BA, Keel, S, Khanal, R, Kishtagari, A, Madanat, Y, Maness, LJ, McCurdy, SR, McMahon, C, Odenike, O, Osman, A, Reddy, VV, Sallman, DA, Sayar, H, Shallis, R, Singh, A, Tanaka, T, Thota, S, Kovach, E, Nguyen, J & Hochstetler, C 2025, 'Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 23, no. 3, pp. 66-75. https://doi.org/10.6004/jnccn.2025.0013

TY - JOUR

T1 - Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines

AU - Greenberg, Peter L.

AU - Stone, Richard M.

AU - Abaza, Yasmin

AU - Al-Kali, Aref

AU - Anand, Sarah

AU - Ball, Brian

AU - Bennett, John M.

AU - Borate, Uma

AU - Brunner, Andrew M.

AU - Chai-Ho, Wanxing

AU - Curtin, Peter

AU - DeZern, Amy E.

AU - Gaensler, Karin

AU - Gahvari, Zhubin

AU - Garcia-Manero, Guillermo

AU - Griffiths, Elizabeth A.

AU - Haque, Tamanna

AU - Jacoby, Meagan

AU - Jonas, Brian A.

AU - Keel, Sioban

AU - Khanal, Rashmi

AU - Kishtagari, Ashwin

AU - Madanat, Yazan

AU - Maness, Lori J.

AU - McCurdy, Shannon R.

AU - McMahon, Christine

AU - Odenike, Olatoyosi

AU - Osman, Afaf

AU - Reddy, Vishnu V.

AU - Sallman, David A.

AU - Sayar, Hamid

AU - Shallis, Rory

AU - Singh, Abhay

AU - Tanaka, Tiffany

AU - Thota, Swapna

AU - Kovach, Emily

AU - Nguyen, Jamie

AU - Hochstetler, Cindy

PY - 2025/3

Y1 - 2025/3

N2 - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

AB - The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

UR - https://www.scopus.com/pages/publications/105000358788

U2 - 10.6004/jnccn.2025.0013

DO - 10.6004/jnccn.2025.0013

M3 - Article

C2 - 40073835

AN - SCOPUS:105000358788

SN - 1540-1405

VL - 23

SP - 66

EP - 75

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 3

ER -

Myelodysplastic Syndromes, Version 2.2025 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this